[Leipzig, Germany – November 2025] – Lambda Biologics has been honored with the BioTech Breakthrough Award for Cell & Gene Therapy Innovation, recognizing the company’s pioneering work in advancing human-relevant organoid platforms that accelerate translational research and enable more predictive development of next-generation cell and gene therapies.
Advancing Human-Relevant Science for Cell & Gene Therapy
Lambda Biologics bridges the gap between discovery and clinical translation through organoid-based testing systems and oncology services that reflect real human biology. By recreating complex tissue microenvironments, these models enable researchers to evaluate how therapeutic candidates – including CAR-T, TCR, and gene-editing modalities – interact with human tissues in vitro.
This human-relevant approach allows researchers to gain deeper insights into therapeutic efficacy, mechanism of action, and safety before clinical trials – supporting faster, more ethical, and data-driven innovation in the rapidly evolving CGT landscape.
Comprehensive Organoid & Oncology Solutions
Lambda Biologics provides:
A diverse biobank of patient-derived and healthy-tissue organoids across multiple disease areas, supporting ready-to-use, customizable research models
Oncology and co-culture services that model the tumor microenvironment (TME) with immune and stromal components – including tumor-infiltrating lymphocytes (TILs), macrophages, and cancer-associated fibroblasts (CAFs)
Tailored assay design and analytical support, integrating molecular profiling, imaging, and spatial biology to accelerate translational insights
MyLab, Lambda’s proprietary digital environment for experiment planning, workflow management, and data interpretation
Aligned with OECD Test Guidelines, FDA’s New Approach Methodologies (NAMs) framework, and NIH Standardized Organoid Modeling (SOM) Center, Lambda Biologics’ platforms offer animal-free, regulatory-ready alternatives for preclinical development.
Recognition for Translational Impact
The BioTech Breakthrough Award highlights Lambda Biologics’ contribution to improving the predictability, efficiency, and ethical standards of preclinical testing. The company’s work is helping the global scientific community transition from animal models toward human-relevant, data-driven methodologies that enhance translational accuracy.
About Lambda Biologics
Based in Leipzig, Germany, Lambda Biologics provides organoid-based products and oncology services that enable high-precision, ethical, and human-relevant research across pharmaceutical, biotech, cosmetic, and food industries. The company integrates expertise in stem cell biology, tissue engineering, and translational science to help clients accelerate innovation and reduce reliance on animal testing.
Learn more: https://afs.lambda-bio.com/
Lambda Biologics’ Oncology Solutions: Patient-derived cancer organoid-based drug evaluation service
Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid
